Inivata Highlights its InVision ctDNA Assay for Broad Molecular Profiling and Presentation of NSCLC data at ASCO Annual Meeting 2016
Inivata Highlights its InVision™ ctDNA Assay for Broad Molecular Profiling and Presentation of NSCLC data at ASCO Annual Meeting 2016
Inivata, a global clinical cancer genomics company employing the precision of circulating tumor DNA (ctDNA) analysis to improve personalized healthcare in oncology, will introduce its proprietary InVision™ ctDNA assay for broad molecular profiling during the 2016 Annual Meeting of the American Society of Clinical Oncology (‘ASCO’) at McCormick Place in Chicago, Illinois, June 3-7, 2016.
The InVision™ assay utilizes the innovative application of Inivata’s proprietary enhanced tagged-amplicon sequencing (eTAm-Seq™) platform for genomic analysis, which was developed by Inivata on the basis of the TAm-Seq™ technology from the Rosenfeld Lab at the Cancer Research UK Cambridge Institute (CRUK-CI), University of Cambridge. InVision™ was developed to serve as a reliable, multi-gene, support tool for oncologists to accurately translate genomic alterations into actionable information to inform clinical decision making and improve cancer treatment planning for the patient. Commercial availability of the InVision™ assay will be the subject of a future announcement.
At ASCO, clinical data from the InVision™ assay in non-small cell lung cancer is being co-presented with Institut Gustave Roussy. The following abstract will be presented during the poster session:
Abstract Title: Evaluation of liquid biopsies for molecular profiling and monitoring in non-small cell lung cancer (NSCLC) patients. (Abstract #: 11533)
Location: Poster Session:Tumor Biology, Hall A, Board Number 230
Date/Time: June 6th, 1:00 – 4:30pm
Presenter: Jordi Remon, MD
Author affiliations: Institut Gustave Roussy and Inivata
Inivata’s representatives will also be exhibiting and providing further details on the impending commercial launch of the InVision™ assay at the ASCO annual meeting booth number 6161. To arrange an interview or meeting please contact us via info@inivata.com
About Inivata
Inivata is a leader in liquid biopsy. Its InVision® platform unlocks essential genomic information from a simple blood draw to guide and personalize cancer treatment, monitor response and detect relapse. Inivata’s technology is based on pioneering research from the Cancer Research UK Cambridge Institute, University of Cambridge. Its lead product, InVisionFirst®-Lung is commercially available and offers best-in-class sensitivity and turnaround, providing molecular insights that enable clinicians to make more informed treatment decisions for advanced NSCLC patients. Inivata has also launched the personalized RaDaR™ assay – allowing the highly sensitive detection of residual disease and recurrence. Inivata is partnering with pharmaceutical, biotechnology companies and commercial partners in a range of early and late stage cancer development programs. The Company has a CLIA certified, CAP accredited laboratory in Research Triangle Park, NC and R&D laboratories in Cambridge, UK. For more information, please go to www.inivata.com. Follow us on Twitter @Inivata.
Media Contacts
Consilium Strategic Communications
Chris Gardner/Angela Gray/Sarah Wilson
Paul Rabin (US)
inivata@consilium-comms.com +44 (0)20 3709 5700, +1 516 503 0271
Karen Chandler-Smith
karen.chandler-smith@inivata.com +44 (0)7900 430235
